Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

stallergenes, 6 rue alexis de tocqueville, antony, francuska - standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides pteronyssinus standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides farinae - sublingvalna tableta - urbroj: jedna sublingvalna tableta sadrži 100 ir ili 300 ir standardiziranog alergenog ekstrakta grinja kućne prašine dermatophagoides pteronyssinus i dermatophagoides farinae u jednakim dijelovima

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

stallergenes, 6 rue alexis de tocqueville, antony, francuska - standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides pteronyssinus standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides farinae - sublingvalna tableta - urbroj: jedna sublingvalna tableta sadrži 100 ir standardiziranog alergenog ekstrakta grinja kućne prašine dermatophagoides pteronyssinus i dermatophagoides farinae

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

stallergenes, 6 rue alexis de tocqueville, antony, francuska - standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides pteronyssinus standardiziran ekstrakt alergena grinja kućne prašine dermatophagoides farinae - sublingvalna tableta - urbroj: jedna sublingvalna tableta sadrži 300 ir standardiziranog alergenog ekstrakta grinja kućne prašine dermatophagoides pteronyssinus i dermatophagoides farinae

Europska Unija - hrvatski - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazola - schizophrenia; bipolar disorder - psycholeptics - aripiprazol mylan pharma je indiciran za liječenje shizofrenije kod odraslih i adolescenata starijih od 15 godina. Арипипразол Майлана pharma je indiciran za liječenje od umjerenih do teških maničnih epizoda kada je bipolarni poremećaj poremećaj i za prevenciju novog manic epizoda kod odraslih, koji su doživjeli pretežno manične epizode, a čiji je manične epizode odgovorio na арипипразол u liječenju. Арипипразол Майлана pharma je indiciran za liječenje do 12 tjedana umjerenih i teških maničnih epizoda u bipolarni poremećaj kod adolescenata u dobi od 13 godina i stariji.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pharmathen s.a. - ibandroninska kiselina - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - lijekovi za liječenje bolesti kostiju - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. liječenje tumor-induced гиперкальциемии sa ili bez metastaza. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Europska Unija - hrvatski - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hipofiza i hipotalamusni hormoni i analozi - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.